Sandoz has not minced words about the massive, yet largely untapped opportunity biosimilar makers are presented with as dozens of branded medicines inch toward the patent cliff in the next decade.& | ...
AbbVie’s CEO Robert Michael is emerging from his sophomore year at the helm with $32.5 million in 2025 compensation, marking a hefty 75% spike from his first-year pay and solidifying the rising chief ...
Pharmas’ direct drug sale platforms could be the key to bridging the sizable gap between patients’ awareness of certain medications and actual prescription numbers, a new survey suggests. | Pharmas’ ...
About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer ...
Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...
In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğur Şahin, M.D., and his wife and CMO Özlem Türeci, M.D. will depart by the end of the year to establish a new ...
After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million). | After nearly nine years ...
The FDA is doubling down on its goal to increase biosimilar drug availability in the U.S. | The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug ...
What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...
Right up front in its proxy filing with the SEC, Eli Lilly took care of justifying its $36.7 mill | With sales booming at Eli Lilly, the Indianapolis company has compensated CEO David Ricks with a $36 ...
In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...
Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results